Jefferies Group Comments on Zoetis Inc.’s FY2018 Earnings (ZTS)
Zoetis Inc. (NYSE:ZTS) – Equities researchers at Jefferies Group reduced their FY2018 earnings per share estimates for shares of Zoetis in a research note issued on Thursday. Jefferies Group analyst J. Holford now expects that the brokerage will earn $2.78 per share for the year, down from their prior forecast of $2.79. Jefferies Group has a “Buy” rating and a $63.00 price objective on the stock. Jefferies Group also issued estimates for Zoetis’ FY2019 earnings at $3.18 EPS and FY2020 earnings at $3.59 EPS.
Several other analysts also recently weighed in on ZTS. Guggenheim restated a “buy” rating and set a $60.00 price objective on shares of Zoetis in a research report on Monday, July 18th. Barclays PLC increased their target price on Zoetis from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Thursday, August 4th. Citigroup Inc. increased their target price on Zoetis from $50.00 to $53.00 and gave the company a “neutral” rating in a research report on Thursday, August 4th. Credit Suisse Group AG reiterated an “outperform” rating and issued a $60.00 target price on shares of Zoetis in a research report on Tuesday, August 23rd. Finally, Argus increased their target price on Zoetis from $54.00 to $58.00 and gave the company a “below average” rating in a research report on Friday, September 9th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $55.50.
Zoetis (NYSE:ZTS) traded up 0.10% during trading on Monday, hitting $51.11. The stock had a trading volume of 1,585,057 shares. The firm has a market capitalization of $25.30 billion, a P/E ratio of 39.81 and a beta of 1.01. Zoetis has a one year low of $38.26 and a one year high of $53.14. The stock has a 50 day moving average of $51.24 and a 200 day moving average of $49.17.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Wednesday, August 3rd. The company reported $0.49 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.05. Zoetis had a return on equity of 77.58% and a net margin of 13.15%. The business had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the previous year, the business posted $0.43 EPS. Zoetis’s revenue for the quarter was up 2.8% on a year-over-year basis.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Thursday, November 3rd will be paid a dividend of $0.095 per share. The ex-dividend date is Tuesday, November 1st. This represents a $0.38 annualized dividend and a yield of 0.74%. Zoetis’s dividend payout ratio is currently 29.69%.
In other Zoetis news, Director Michael B. Mccallister bought 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 6th. The stock was acquired at an average price of $51.34 per share, with a total value of $102,680.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Heidi C. Chen sold 32,097 shares of the firm’s stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of $50.98, for a total value of $1,636,305.06. Following the sale, the insider now directly owns 46,060 shares of the company’s stock, valued at approximately $2,348,138.80. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA boosted its stake in shares of Zoetis by 114.1% in the second quarter. Massachusetts Financial Services Co. MA now owns 8,738,248 shares of the company’s stock worth $414,717,000 after buying an additional 4,656,765 shares during the period. Alliancebernstein L.P. boosted its stake in shares of Zoetis by 49.9% in the second quarter. Alliancebernstein L.P. now owns 7,634,826 shares of the company’s stock worth $362,349,000 after buying an additional 2,542,023 shares during the period. Vanguard Group Inc. boosted its stake in shares of Zoetis by 6.5% in the second quarter. Vanguard Group Inc. now owns 29,819,968 shares of the company’s stock worth $1,415,256,000 after buying an additional 1,812,428 shares during the period. Marsico Capital Management LLC boosted its stake in shares of Zoetis by 321.7% in the second quarter. Marsico Capital Management LLC now owns 2,106,745 shares of the company’s stock worth $99,986,000 after buying an additional 1,607,218 shares during the period. Finally, Emerald Acquisition Ltd. purchased a new stake in shares of Zoetis during the second quarter worth approximately $69,154,000. 93.14% of the stock is owned by institutional investors and hedge funds.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.